Source: digitaland.gather.com
Showing posts with label High-speed rail: Lobbyists. Show all posts
Showing posts with label High-speed rail: Lobbyists. Show all posts
Sunday, April 4, 2010
Health Care Lobbying now a Chronic Condition in Washington
Source: digitaland.gather.com
Sunday, January 17, 2010
Drug lobbying group threatens to pull support from health care bill
The lead lobbying arm of the drug industry is threatening to pull its support for health care legislation if Democrats reduce protections for brand-name biologic drugs.
In an e-mail obtained by CNN, Billy Tauzin, the top executive of the Pharmaceutical Research and Manufacturers of America (PhRMA), told board members that "we could not support the bill" if Democrats reduce the number of years that brand name biologic drugs can keep their patents. Tauzin's e-mail was also a call to action, saying, "please activate immediately all of your contacts."
PhRMA fought hard for language that passed both the House and Senate health care bills, stating that patents for brand name biologic drugs are protected for 12 years before generic companies would be permitted to make less-expensive versions. Biologics are drugs made from living organisms to prevent and treat diseases like arthritis and diabetes.
At issue now: some Democrats who support the generics industry are trying to use negotiations over a final health care bill to shave off a few years from the 12-year brand exclusivity. The leading Democrat pushing for the change is House Energy and Commerce Chairman Henry Waxman, D-California, a defender of generic drugs who lost a battle early on in his own committee to reduce brand-name protection to seven years.
President Obama signaled in a private meeting with House Democrats Thursday that he could support reducing 12-year protection for brand-name biologics.
According to several Democratic sources, Rep. Anna Eshoo, D-California, a lawmaker with biotech companies in her Silicon Valley district, challenged the president in Thursday's meeting and asked him not to change the 12-year biologics protection.
The sources said Obama responded by making clear he disagreed with her, saying, "My job is to do what I think is good policy."
That sounded alarm bells at PhRMA, which represents drug companies in Washington, and at the Biotechnology Industry Organization -- the lobbying arm of biologic brand drugs.
"Fair data protection of at least 12 years for new, innovative biologic medicines is critically important to the future of medical progress in America. Fair data protection allows our companies to make the extensive investment necessary to develop cutting-edge medicines that allow American patients to live longer, healthier and more productive lives," said PhRMA in a statement.
Supporters of so-called biogeneric drugs argue 12 years of exclusivity is excessive and will undermine innovation, and deny consumer access to more affordable drugs.
The Obama administration and Democratic leaders struck a deal early on to get the powerful lobby on their side during this debate. PhRMA spent millions in advertising in support of Democrats efforts and agreed that drug companies would contribute $80 billion to help defray the cost to the government of reforming health care.
Democratic sources said they were considering asking drug companies for $10 billion more as they negotiate a final health care bill.
Source:cnn.com/
In an e-mail obtained by CNN, Billy Tauzin, the top executive of the Pharmaceutical Research and Manufacturers of America (PhRMA), told board members that "we could not support the bill" if Democrats reduce the number of years that brand name biologic drugs can keep their patents. Tauzin's e-mail was also a call to action, saying, "please activate immediately all of your contacts."
PhRMA fought hard for language that passed both the House and Senate health care bills, stating that patents for brand name biologic drugs are protected for 12 years before generic companies would be permitted to make less-expensive versions. Biologics are drugs made from living organisms to prevent and treat diseases like arthritis and diabetes.
At issue now: some Democrats who support the generics industry are trying to use negotiations over a final health care bill to shave off a few years from the 12-year brand exclusivity. The leading Democrat pushing for the change is House Energy and Commerce Chairman Henry Waxman, D-California, a defender of generic drugs who lost a battle early on in his own committee to reduce brand-name protection to seven years.
President Obama signaled in a private meeting with House Democrats Thursday that he could support reducing 12-year protection for brand-name biologics.
According to several Democratic sources, Rep. Anna Eshoo, D-California, a lawmaker with biotech companies in her Silicon Valley district, challenged the president in Thursday's meeting and asked him not to change the 12-year biologics protection.
The sources said Obama responded by making clear he disagreed with her, saying, "My job is to do what I think is good policy."
That sounded alarm bells at PhRMA, which represents drug companies in Washington, and at the Biotechnology Industry Organization -- the lobbying arm of biologic brand drugs.
"Fair data protection of at least 12 years for new, innovative biologic medicines is critically important to the future of medical progress in America. Fair data protection allows our companies to make the extensive investment necessary to develop cutting-edge medicines that allow American patients to live longer, healthier and more productive lives," said PhRMA in a statement.
Supporters of so-called biogeneric drugs argue 12 years of exclusivity is excessive and will undermine innovation, and deny consumer access to more affordable drugs.
The Obama administration and Democratic leaders struck a deal early on to get the powerful lobby on their side during this debate. PhRMA spent millions in advertising in support of Democrats efforts and agreed that drug companies would contribute $80 billion to help defray the cost to the government of reforming health care.
Democratic sources said they were considering asking drug companies for $10 billion more as they negotiate a final health care bill.
Source:cnn.com/
Thursday, December 10, 2009
High-speed rail: Lobbyists clamor for stimulus money
WASHINGTON - -- Stimulus money for high-speed rail has sparked a feeding frenzy among lobbyists, according to a new report from a watchdog group.
Competition for federal stimulus grants led more than 50 groups to lobby on high-speed rail policy in the third quarter of 2009, the Center for Public Integrity reports. That number is roughly triple the 17 groups doing so just a year earlier.
Thirty-seven states and the District of Columbia made requests totaling $57 billion, according to the Federal Railroad Administration. Only $8 billion is available.
As a result, states, cities and manufacturing companies rushed to hire lobbyists to push their interests.
One example is Los Angeles, which would benefit from a rail link to San Francisco. It hired high-powered lobbying firm Patton Boggs.
General Electric, Siemens, steelmaker Arcelor Mittal and commercial rail giant Norfolk Southern are also lobbying on the issue, said Matthew Lewis, author of the group's article.
"I don't think this rise in lobbying is a bad thing," Lewis said. "It's just important to note and scrutinize how decisions are going to be shaped."
Lewis added that his report is "dramatically underestimating" the number of groups lobbying on high-speed rail because lobbyists can list their work in broad areas, like transportation, rather than specific subjects.
And because disclosure forms cover lobbying on multiple issues, it is almost impossible to estimate how much is spent on high-speed rail. But experts agree: more than last year.
High-speed rail advocates were happy to see the expansion of lobbying.
"I would like to see hundreds and hundreds of lobbying firms working for high-speed rail," said Richard Harnish, executive director of the Midwest High Speed Rail Association. "This is a very, very big issue. There's a lot that needs to be done."
Source:chicagotribune.com/
Competition for federal stimulus grants led more than 50 groups to lobby on high-speed rail policy in the third quarter of 2009, the Center for Public Integrity reports. That number is roughly triple the 17 groups doing so just a year earlier.
Thirty-seven states and the District of Columbia made requests totaling $57 billion, according to the Federal Railroad Administration. Only $8 billion is available.
As a result, states, cities and manufacturing companies rushed to hire lobbyists to push their interests.
One example is Los Angeles, which would benefit from a rail link to San Francisco. It hired high-powered lobbying firm Patton Boggs.
General Electric, Siemens, steelmaker Arcelor Mittal and commercial rail giant Norfolk Southern are also lobbying on the issue, said Matthew Lewis, author of the group's article.
"I don't think this rise in lobbying is a bad thing," Lewis said. "It's just important to note and scrutinize how decisions are going to be shaped."
Lewis added that his report is "dramatically underestimating" the number of groups lobbying on high-speed rail because lobbyists can list their work in broad areas, like transportation, rather than specific subjects.
And because disclosure forms cover lobbying on multiple issues, it is almost impossible to estimate how much is spent on high-speed rail. But experts agree: more than last year.
High-speed rail advocates were happy to see the expansion of lobbying.
"I would like to see hundreds and hundreds of lobbying firms working for high-speed rail," said Richard Harnish, executive director of the Midwest High Speed Rail Association. "This is a very, very big issue. There's a lot that needs to be done."
Source:chicagotribune.com/
Subscribe to:
Posts (Atom)